These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 21693736)
1. Standard- vs high-dose clopidogrel after percutaneous coronary intervention. Patti G; Pasceri V; Di Sciascio G JAMA; 2011 Jun; 305(24):2520-1; author reply 2521-2. PubMed ID: 21693736 [No Abstract] [Full Text] [Related]
2. Standard- vs high-dose clopidogrel after percutaneous coronary intervention. Jeong YH; Park Y; Kim IS JAMA; 2011 Jun; 305(24):2520; author reply 2521-2. PubMed ID: 21693737 [No Abstract] [Full Text] [Related]
3. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. Price MJ; Berger PB; Teirstein PS; Tanguay JF; Angiolillo DJ; Spriggs D; Puri S; Robbins M; Garratt KN; Bertrand OF; Stillabower ME; Aragon JR; Kandzari DE; Stinis CT; Lee MS; Manoukian SV; Cannon CP; Schork NJ; Topol EJ; JAMA; 2011 Mar; 305(11):1097-105. PubMed ID: 21406646 [TBL] [Abstract][Full Text] [Related]
4. An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. Gurbel PA; Tantry US JAMA; 2011 Mar; 305(11):1136-7. PubMed ID: 21406654 [No Abstract] [Full Text] [Related]
5. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW; JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378 [TBL] [Abstract][Full Text] [Related]
6. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Siller-Matula JM; Huber K; Christ G; Schrör K; Kubica J; Herkner H; Jilma B Heart; 2011 Jan; 97(2):98-105. PubMed ID: 20736210 [TBL] [Abstract][Full Text] [Related]
7. Erratum for Fernandez et al. “Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE Study)” Am J Cardiol 2011;107: 6 –9. Am J Cardiol; 2012 Mar; 109(6):924. PubMed ID: 22489318 [No Abstract] [Full Text] [Related]
8. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470 [TBL] [Abstract][Full Text] [Related]
9. Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. Varenhorst C; Koul S; Erlinge D; Lagerqvist B; Siegbahn A; Wallentin L; James S Am Heart J; 2011 Aug; 162(2):363-71. PubMed ID: 21835299 [TBL] [Abstract][Full Text] [Related]
10. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E; Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526 [TBL] [Abstract][Full Text] [Related]
11. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435 [TBL] [Abstract][Full Text] [Related]
12. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial. Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058 [TBL] [Abstract][Full Text] [Related]
13. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML JACC Cardiovasc Interv; 2008 Dec; 1(6):612-9. PubMed ID: 19463374 [TBL] [Abstract][Full Text] [Related]
14. Comparison of 600 versus 300-mg clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. Lin GM; Li YH Am J Cardiol; 2011 Feb; 107(4):641. PubMed ID: 21295179 [No Abstract] [Full Text] [Related]
15. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Welsh RC; Rao SV; Zeymer U; Thompson VP; Huber K; Kochman J; McClure MW; Gretler DD; Bhatt DL; Gibson CM; Angiolillo DJ; Gurbel PA; Berdan LG; Paynter G; Leonardi S; Madan M; French WJ; Harrington RA; Circ Cardiovasc Interv; 2012 Jun; 5(3):336-46. PubMed ID: 22647518 [TBL] [Abstract][Full Text] [Related]
16. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM; Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975 [TBL] [Abstract][Full Text] [Related]
17. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Mehta SR; Tanguay JF; Eikelboom JW; Jolly SS; Joyner CD; Granger CB; Faxon DP; Rupprecht HJ; Budaj A; Avezum A; Widimsky P; Steg PG; Bassand JP; Montalescot G; Macaya C; Di Pasquale G; Niemela K; Ajani AE; White HD; Chrolavicius S; Gao P; Fox KA; Yusuf S; Lancet; 2010 Oct; 376(9748):1233-43. PubMed ID: 20817281 [TBL] [Abstract][Full Text] [Related]
18. High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. Liang J; Wang Z; Shi D; Liu Y; Zhao Y; Han H; Li Y; Liu W; Zhang L; Yang L; Zhou Y Angiology; 2015 Apr; 66(4):319-25. PubMed ID: 24913197 [TBL] [Abstract][Full Text] [Related]
19. Is clopidogrel adequate in 2013? Wheatcroft S Cardiovasc J Afr; 2013 Mar; 24(2):45. PubMed ID: 23750347 [No Abstract] [Full Text] [Related]
20. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ; Mehta SR; Bassand JP; Chrolavicius S; Diaz R; Eikelboom JW; Fox KA; Granger CB; Jolly S; Joyner CD; Rupprecht HJ; Widimsky P; Afzal R; Pogue J; Yusuf S N Engl J Med; 2010 Sep; 363(10):930-42. PubMed ID: 20818903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]